List of Excipients in Branded Drug 3M DURAPREP SURGICAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Solventum US LLC	3M DURAPREP SURGICAL	iodine povacrylex and isopropyl alcohol	17518-011	ALCOHOL
Solventum US LLC	3M DURAPREP SURGICAL	iodine povacrylex and isopropyl alcohol	17518-011	WATER

3M DuraPrep Surgical Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 7, 2026

3M DuraPrep Surgical Solution is an alcohol-based, iodine-containing topical antiseptic used for preoperative skin preparation. Its commercial differentiation comes from the combination of rapid alcohol activity, persistent iodine activity, film-forming excipient technology, applicator design, and operating-room workflow rather than from the active ingredients alone. The main opportunities are private-label antiseptic products, improved applicators, reduced flammability risk, skin-tolerability optimization, antimicrobial-resistance positioning, and hospital conversion programs.

What is 3M DuraPrep Surgical Solution?

DuraPrep is a ready-to-use surgical skin preparation containing iodine povacrylex and isopropyl alcohol. The product is applied before surgery to reduce bacteria on intact skin. The alcohol provides rapid antimicrobial activity, while the iodine complex supports broader and more persistent antiseptic action after application.

Product characteristic	DuraPrep profile
Manufacturer	3M Company, with healthcare products now associated with Solventum following the 2024 3M healthcare separation
Product type	Topical surgical antiseptic
Dosage form	Liquid solution delivered through a single-use applicator
Active antiseptic system	Iodine povacrylex and isopropyl alcohol
Alcohol concentration	Approximately 74% w/w isopropyl alcohol, according to product labeling
Iodine system	Approximately 8.5% w/w iodine povacrylex, equivalent to about 0.7% available iodine
Primary use	Preoperative preparation of intact skin
Regulatory category	Surgical antiseptic regulated under FDA topical antiseptic requirements
Orange Book status	Generally not an Orange Book-listed prescription drug product
Biosimilar relevance	None; DuraPrep is a chemical topical antiseptic, not a biologic

The product should be evaluated as a drug-device combination from a commercial and formulation perspective. The solution is important, but the applicator controls dose delivery, coverage, user contact, drying behavior, and operating-room handling.

What excipients are used in DuraPrep?

The principal excipient strategy is a film-forming iodine delivery system in a high-concentration alcohol vehicle. Public product labeling identifies iodine povacrylex and isopropyl alcohol as the active ingredients; formulation components may include water and polymeric or solvent materials used to stabilize the iodine complex, control viscosity, and form a residual film.[1]

Excipient functions

Formulation component	Functional role	Commercial significance
Isopropyl alcohol	Rapid antimicrobial activity and volatile carrier	Drives fast kill and rapid drying; also creates flammability and skin-drying constraints
Iodine povacrylex	Iodine reservoir and film-forming antiseptic complex	Supports persistent antimicrobial activity after alcohol evaporation
Copovidone or related polymer	Film formation, iodine complex stabilization, adhesion to skin	Differentiates the formulation from simple povidone-iodine solutions
Purified water	Solvent and viscosity control	Affects drying time, iodine availability, and skin feel
Packaging and applicator materials	Controlled delivery and dose distribution	Can determine regulatory classification, usability, waste, and manufacturing cost

The excipient strategy has four technical objectives:

1. Keep the iodine complex stable during shelf life.
2. Deliver high alcohol activity without excessive irritation.
3. Leave a coherent residual film after drying.
4. Maintain uniform coverage through the applicator.

A competing product that simply combines povidone-iodine with alcohol may match the active ingredients but fail to reproduce DuraPrep’s drying profile, residual film, applicator performance, or clinical workflow.

How does DuraPrep compare with chlorhexidine surgical preparations?

DuraPrep competes primarily with chlorhexidine gluconate in alcohol, especially products such as BD ChloraPrep. The commercial decision often depends on site-specific efficacy, contraindications, institutional protocols, cost, and surgeon preference.

Attribute	DuraPrep	Alcoholic chlorhexidine preparation
Principal antiseptic system	Iodine povacrylex plus isopropyl alcohol	Chlorhexidine gluconate plus alcohol
Rapid alcohol effect	Yes	Yes
Residual activity	Provided by iodine film system	Provided by chlorhexidine substantivity
Formulation differentiator	Iodine-containing film	Cationic chlorhexidine deposition
Main safety constraints	Alcohol flammability, ocular and mucosal restrictions, iodine-related concerns	Severe eye and ear toxicity concerns, allergy risk, use restrictions
Primary commercial advantage	Persistent iodine film and broad surgical familiarity	Strong institutional adoption and high perceived persistence
Substitution risk	High in formularies with chlorhexidine preference	High where iodine-based preparations are preferred

FDA labeling for surgical antiseptics requires specific warnings concerning flammability, pooling under patients, contact with eyes and mucous membranes, and use near ignition sources.[1,2] These warnings create opportunities for differentiated applicators and packaging, regardless of the antiseptic chemistry.

What formulation patents protect DuraPrep?

The strongest intellectual-property position is likely to reside in formulation combinations, iodine-polymer complexes, applicator architecture, packaging, and manufacturing controls rather than in broad ownership of isopropyl alcohol or iodine as active materials.

Potentially protectable claim categories include:

• Iodine povacrylex compositions with defined available-iodine levels.
• Alcohol-to-water ratios that balance drying time and iodine release.
• Film-forming copolymer systems.
• Stabilized iodine complexes with controlled precipitation or discoloration.
• Single-use applicators that meter a defined volume.
• Applicator geometries that reduce pooling and improve coverage.
• Packaging configurations that limit alcohol evaporation.
• Manufacturing processes that maintain iodine concentration and polymer uniformity.
• Methods for preparing skin before invasive procedures.
• Combination use with adhesive surgical drapes.

A definitive patent-family determination requires a current search of 3M, Solventum, and predecessor assignee records in the United States and relevant foreign jurisdictions. The product’s commercial position should not be assessed solely from Orange Book data because topical antiseptic products may not have the same listing structure as prescription tablets, injectables, or biologics.

What is the Orange Book status of DuraPrep?

DuraPrep is not generally treated as an Orange Book-centered product. The Orange Book primarily identifies approved prescription drug products and certain approved over-the-counter products with FDA application records. Surgical antiseptic products marketed under FDA monograph or related regulatory pathways may have limited or no Orange Book information compared with conventional prescription drugs.[3]

This has four practical consequences:

1. There may be no conventional Orange Book patent-listing pathway.
2. A competing manufacturer may not need to resolve listed patents through a Paragraph IV certification.
3. Patent disputes may proceed through ordinary federal litigation rather than an automatic Hatch-Waxman filing dispute.
4. Regulatory strategy may focus on monograph compliance, product labeling, manufacturing controls, and device compatibility.

When does DuraPrep lose exclusivity?

DuraPrep does not have a single, readily identifiable small-molecule exclusivity date comparable to a patented prescription drug. Market access depends on the interaction of regulatory status, formulation patents, applicator patents, trademarks, manufacturing know-how, hospital contracts, and product-performance data.

Exclusivity layer	Likely relevance
New chemical entity exclusivity	Low; the product uses established antiseptic ingredients
Prescription drug exclusivity	Limited or not central to the commercial model
Orange Book-listed patents	Not the primary barrier
Formulation patents	Potentially important
Device and applicator patents	Potentially important
Trademark protection	Important for DuraPrep brand recognition
Trade secrets	Important for iodine stability, filling, packaging, and quality control
Hospital contracts	Important for practical market access
Clinical and usability evidence	Important for conversion from incumbent products

A generic or private-label entrant could therefore reach the market without waiting for a single patent expiration if it develops a compliant formulation, demonstrates product quality, secures an acceptable applicator, and avoids enforceable formulation or device claims.

What Paragraph IV challenges or litigation affect DuraPrep?

No major, publicly established Paragraph IV campaign is central to DuraPrep’s market position. That outcome is consistent with the product’s regulatory category and the absence of a conventional prescription-drug patent listing strategy.

Potential litigation risks remain in four areas:

Formulation patent litigation

A competitor could challenge patents covering iodine-polymer complexes, available-iodine levels, solvent ratios, or film-forming systems. Claims that require a narrow concentration range may be vulnerable to invalidity or design-around arguments if earlier povidone-iodine and alcohol compositions disclose overlapping ranges.

Applicator patent litigation

Applicator patents may be more commercially important than composition patents. Claims can cover sponge geometry, frangible seals, internal reservoirs, flow control, and application surfaces. A competitor can often avoid infringement through a redesigned applicator, but this may increase development and validation costs.

Trade-dress and trademark disputes

The DuraPrep name, packaging appearance, and product presentation may have brand value. A private-label product that copies packaging or applicator appearance could face trademark or trade-dress exposure even if its formulation is lawful.

Product-liability disputes

Alcohol-based skin preparations create litigation exposure if pooling, incomplete drying, or ignition occurs in the operating room. Packaging instructions, applicator controls, warnings, and hospital training directly affect this risk.

What manufacturing and intellectual-property barriers exist?

The formulation is technically reproducible at a high level, but commercial equivalence is more difficult. Key manufacturing barriers include:

• Maintaining uniform iodine content across the fill volume.
• Preventing iodine loss, discoloration, precipitation, and container interaction.
• Controlling alcohol evaporation during filling and storage.
• Producing an applicator that delivers a consistent dose.
• Validating microbial quality for a low-water, high-alcohol system.
• Managing flammable-liquid production and warehouse requirements.
• Demonstrating container-closure integrity.
• Ensuring compatibility between the solution, sponge, plastic reservoir, label, and packaging.
• Establishing drying-time and coverage specifications.
• Meeting hospital requirements for single-use products and lot traceability.

An entrant with an inexpensive liquid but an inferior applicator may have difficulty displacing DuraPrep. Hospitals purchase the complete preparation system, not only the active ingredients.

What commercial opportunities exist for DuraPrep-like excipient systems?

Private-label surgical antiseptics

Hospitals and group purchasing organizations may accept a lower-cost equivalent if it offers comparable drying, coverage, shelf life, and applicator performance. A private-label product can target ambulatory surgery centers, community hospitals, veterinary surgery, and international markets.

Improved film-forming polymers

A next-generation polymer could target faster drying, lower tack, reduced residue, lower skin irritation, or improved compatibility with adhesive drapes. The value proposition must be measurable because hospitals may not pay a premium for an excipient change that does not improve workflow or outcomes.

Low-flammability delivery

The alcohol vehicle creates unavoidable flammability concerns at conventional concentrations. Opportunities include controlled-dose applicators, reduced pooling, visual coverage indicators, and packaging that reduces accidental spills. A lower-alcohol formulation may be commercially attractive but would require evidence that antimicrobial performance remains acceptable.

Sensitive-skin and allergy positioning

Some institutions seek alternatives for patients with chlorhexidine sensitivity or concerns about iodine exposure. A product with lower irritation, clearer contraindication management, or differentiated polymer deposition could occupy a targeted segment. Claims must remain within the applicable regulatory framework.

Specialized surgical applications

Potential segments include orthopedic surgery, cardiovascular procedures, obstetrics, dermatology, outpatient procedures, and veterinary surgery. Each segment has different requirements for drying, adhesive compatibility, mucosal exclusion, and residual film.

Sustainable packaging

Single-use applicators generate substantial plastic and packaging waste. Reduced-material applicators, recyclable components, lower-volume formats, and packaging with less secondary material could support procurement programs. The product must preserve alcohol retention and container-closure performance.

How strong is the DuraPrep patent estate?

The likely estate strength is mixed.

Asset category	Relative strength	Reason
Core iodine and alcohol actives	Low	Established ingredients with extensive prior art
Narrow iodine-polymer formulation claims	Moderate	May protect specific ratios and performance characteristics
Film-forming delivery system	Moderate to high	Functional combination may be harder to reproduce without overlap
Single-use applicator	Moderate to high	Mechanical claims can create practical barriers
Manufacturing process	Moderate	Trade secrets may matter more than published patents
Trademark and brand	High commercially	Brand recognition supports hospital retention
Clinical differentiation	Moderate	Evidence and workflow familiarity can resist substitution
Biosimilar protection	None	Product is not a biologic

The strongest barrier is likely the integrated product system: formulation, applicator, packaging, labeling, supply reliability, and hospital contracts. A competitor must clear each layer.

What generic launch scenarios exist?

Scenario 1: Direct formulation substitute

A competitor markets an iodine-alcohol surgical preparation with a similar concentration profile and a basic applicator. This is the fastest and lowest-cost route but carries the greatest risk of inferior usability and weak hospital adoption.

Scenario 2: Design-around private label

The entrant uses a different polymer, applicator geometry, or packaging format to avoid formulation and device claims. The product may enter through regional hospital systems and ambulatory surgery centers.

Scenario 3: Chlorhexidine conversion

A hospital replaces DuraPrep with an alcoholic chlorhexidine product based on formulary economics or institutional preference. This is the most immediate competitive threat where chlorhexidine is permitted for the surgical site.

Scenario 4: Premium differentiated product

A new product claims faster drying, lower residue, easier coverage, reduced packaging waste, or improved adhesive compatibility. This strategy requires comparative usability and safety evidence and may support premium pricing.

What revenue exposure does DuraPrep face?

Revenue exposure is concentrated in hospital procedure volume, operating-room contracts, distributor relationships, and group purchasing agreements. The main risks are:

• Formulary conversion to alcoholic chlorhexidine.
• Lower-cost private-label products.
• Hospital budget pressure and product standardization.
• Supply disruptions or applicator shortages.
• Safety-driven restrictions on alcohol-based preparations.
• Declining procedure volumes in specific hospital segments.
• Loss of contracts following a healthcare business divestiture or supplier transition.

The main defenses are reliable supply, surgeon familiarity, validated application performance, contract integration, and evidence supporting use where chlorhexidine is unsuitable or restricted.

How does DuraPrep compare with other surgical antiseptic opportunities?

DuraPrep-like products offer a more accessible entry point than biologics or complex injectable drugs because the active ingredients are established and the manufacturing process is comparatively simple. The tradeoff is greater price competition and lower regulatory exclusivity.

Opportunity	Regulatory complexity	Patent dependence	Commercial margin potential
DuraPrep-like antiseptic	Moderate	Moderate	Moderate
Alcoholic chlorhexidine preparation	Moderate	Moderate to high	Moderate to high
Novel topical antiseptic	High	High	High if differentiated
Injectable generic	High	High	Variable
Biosimilar	Very high	High	High but capital intensive

Key Takeaways

• DuraPrep is an iodine-povacrylex and isopropyl-alcohol surgical antiseptic delivered through a single-use applicator.
• Its excipient strategy depends on polymeric film formation, iodine stabilization, rapid alcohol evaporation, and controlled skin coverage.
• The product is not primarily protected through a conventional Orange Book and Paragraph IV framework.
• Formulation, applicator, packaging, manufacturing know-how, trademark, and hospital contracts are the relevant commercial barriers.
• The most credible entry opportunities are private-label products, improved applicators, lower-residue formulations, sustainable packaging, and targeted alternatives for chlorhexidine-sensitive settings.
• A direct chemical substitute is easier to develop than a commercially equivalent product because operating-room usability and hospital procurement materially affect adoption.
• Biosimilar risk is not applicable.
• The principal competitive threat is substitution by alcoholic chlorhexidine products and lower-cost surgical antiseptic systems.

FAQs About DuraPrep Excipient Strategy and Commercial Entry

Is DuraPrep a prescription drug?

DuraPrep is a topical surgical antiseptic rather than a conventional prescription medicine. Its regulatory treatment is tied to FDA antiseptic requirements, labeling, manufacturing controls, and applicator configuration.

Can a company launch a generic version of DuraPrep?

A company can potentially launch a competing iodine-alcohol surgical antiseptic if it meets applicable FDA requirements and avoids enforceable formulation, device, trademark, and packaging rights. The product may not follow a conventional abbreviated new drug application pathway used for prescription tablets.

What is the main formulation advantage of iodine povacrylex?

Iodine povacrylex acts as an iodine reservoir and film-forming system. It is designed to retain antiseptic activity on skin after the volatile alcohol component evaporates.

Is DuraPrep interchangeable with ChloraPrep?

The products compete in the same surgical skin-preparation market but are not automatically interchangeable. Institutional protocols must account for active ingredients, anatomical restrictions, drying time, flammability, allergy history, and labeling.

Which excipient innovation has the highest commercial potential?

Applicator and film-forming improvements have the clearest commercial potential because they can affect drying time, coverage, residue, skin tolerability, safety, and operating-room workflow without relying on a new antiseptic active ingredient.

References

1. 3M Company. (2023). DuraPrep surgical solution product labeling. U.S. Food and Drug Administration, DailyMed.

2. U.S. Food and Drug Administration. (2022). Topical antiseptic products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. Part 333.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

4. 3M Company. (2023). DuraPrep surgical solution product information and application instructions. 3M Health Care.

5. U.S. Food and Drug Administration. (2016). Safety and effectiveness of health care antiseptics: Topical antimicrobial drug products for over-the-counter human use. Federal Register.